P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells.
P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer …

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance
is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical …

Defective clearance mechanisms lead to the accumulation of amyloid-beta (Aβ) peptides in
the Alzheimer's brain. Though predominantly generated in neurons, little is known about …

Paclitaxel-induced peripheral neuropathy (PIPN) is a barrier to effective cancer treatment
and impacts quality of life among patients with cancer. We used a translational approach to …

The blood–brain barrier is a physiological barrier that can prevent both small and complex
drugs from reaching the brain to exert a pharmacological effect. For treatment of …

Simple Summary The cellular mechanisms of drug resistance prevent the correct efficacy of
the therapies used in various types of cancer and nanotechnology has been postulated as a …

Chemotherapy remains a mainstay in the treatment of many types of cancer even though it is
associated with debilitating behavioral side effects referred to as “chemobrain,” including …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common and dose‐limiting
toxicity to widely used chemotherapeutics. Although the exact molecular mechanism of …

For reversing the treatment failure in P-glycoprotein (P-gp)-associated MDR (multidrug
resistance) of breast cancer, a high dose of Lapatinib (Lap), a substrate of breast cancer …

Opioids are widely used in cancer and non-cancer pain management. However, many
transporters at the blood–brain barrier (BBB), such as P-glycoprotein (P-gp, ABCB1/MDR1) …